Lixisenatide
- TRADE NAMES: Adlyxin (Sanofi-Aventis); Lyxumia (Sanofi-Aventis); Soliqua (Sanofi-Aventis)
- INDICATIONS: To improve glycemic control in adults with Type II diabetes mellitus
- CLASS: Antidiabetic, Glucagon-like peptide-1 (GLP-1) receptor agonist
- HALF-LIFE: 3 hours
FDA APPROVAL DATE: 07/27/2016
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
PREGNANCY CATEGORY: N/A
Use during pregnancy only if the potential benefit justifies the potential risk to the fetus
Soliqua is lixisenatide and insulin glargine.
Please login to see the rest of this drug profile
SKIN.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
LOCAL.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
